Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 10.

Dummer, R; Hauschild, A; Lindenblatt, N; Pentheroudakis, G; Keilholz, U (2015). Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 26 Suppl:v126-v132.

Dummer, R; Hauschild, A; Guggenheim, M; Keilholz, U; Pentheroudakis, G (2012). Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23(Sup7):vii86-vii91.

Eggermont, A M M; Suciu, S; Testori, A; Kruit, W H; Marsden, J; Punt, C J; Santinami, M; Salès, F; Schadendorf, D; Patel, P; Dummer, R; Robert, C; Keilholz, U; Yver, A; Spatz, A (2012). Ulceration and stage are predictive of interferon efficacy in melanoma: Results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. European Journal of Cancer, 48(2):218-225.

Patel, P M; Suciu, S; Mortier, L; Kruit, W H; Robert, C; Schadendorf, D; Trefzer, U; Punt, C J A; Dummer, R; Davidson, N; Becker, Juergen; Conry, R; Thompson, J A; Hwu, W J; Engelen, K; Agarwala, S S; Keilholz, U; Eggermont, A M M; Spatz, A (2011). Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). European Journal of Cancer, 47(10):1476-1483.

Bottomley, A; Coens, C; Suciu, S; Santinami, M; Kruit, W; Testori, A; Marsden, J; Punt, C; Salès, F; Gore, M; Mackie, R; Kusic, Z; Dummer, R; Patel, P; Schadendorf, D; Spatz, A; Keilholz, U; Eggermont, A (2009). Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. Journal of Clinical Oncology, 27(18):2916-2923.

Garbe, C; Schadendorf, D; Stolz, W; Volkenandt, M; Reinhold, U; Kortmann, R D; Kettelhack, C; Frerich, B; Keilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R; Hauschild, A (2008). Short German guidelines: malignant melanoma. Journal der Deutschen Dermatologischen Gesellschaft, 6(Suppl ):S9-S14.

Garbe, C; Hauschild, A; Volkenandt, M; Schadendorf, D; Stolz, W; Reinhold, U; Kortmann, R D; Kettelhack, C; Frerich, B; Keilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R (2008). Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Research, 18(2):152-160.

Garbe, C; Hauschild, A; Volkenandt, M; Schadendorf, D; Stolz, W; Reinhold, U; Kortmann, R D; Kettelhack, C; Frerich, B; Keilholz, U; Dummer, R; Sebastian, G; Tilgen, W; Schuler, G; Mackensen, A; Kaufmann, R (2008). Evidence and interdisciplinary consensus-based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Research, 18(1):61-67.

Eggermont, A M M; Suciu, S; Santinami, M; Testori, A; Kruit, W H J; Marsden, J; Punt, C J A; Salès, F; Gore, M; Mackie, R; Kusic, Z; Dummer, R; Hauschild, A; Musat, E; Spatz, A; Keilholz, U (2008). Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet, 372(9633):117-126.

Dummer, R; Welters, H; Keilholz, U; Tilgen, W; Burg, G (1990). Interleukin 2: immunologic background and clinical use in tumor therapy. Der Hautarzt, 41(2):53-55.

This list was generated on Thu Nov 23 16:32:28 2017 CET.